MetaCap

Journey Medical (DERM) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed Journey Medical (DERM) over the past year, gaining 3.0% versus a loss of 55.8%. Over five years, DERM leads with a -61.1% price change compared with -92.5% for PDSB. PDS Biotechnology is the larger company by market cap ($95.4 million vs $93.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DERM-55.76%PDSB+2.97%
+121%+19%-83%
Nov 21, 20251 yearNov 20, 2026
DERM-62.46%PDSB-92.26%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DERM versus PDSB key metrics
MetricDERMPDSB
Share price$3.30$0.7774
Market cap$93.16M$95.39M
1-day change-7.04%-3.70%
YTD return-57.20%+0.96%
1-year return-55.76%+2.97%
5-year return-61.13%-92.46%
EPS (TTM)$-0.18$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$61.86M—
Revenue growth (YoY)+10.20%—
Net income (latest FY)$-11.43M$-34.50M
Gross margin66.17%—
Operating margin-13.21%—
Net margin-18.48%—
52-week high$9.56$1.79
52-week low$3.21$0.195
Distance from 52-week high-65.46%-56.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+286.36%+478.85%
Average volume190.39K25.64M
Shares outstanding22.23M122.70M
Employees5821
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed DERM by 58.7 percentage points over the past year.

About Journey Medical

DERM stock →

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

DERM vs PDSB FAQ

Which is bigger, Journey Medical or PDS Biotechnology?

PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $93.16M for Journey Medical (DERM).

Which stock has performed better over the past year, DERM or PDSB?

PDSB returned +2.97% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.

Are Journey Medical and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons